CohBar to Announce Second Quarter 2022 Financial Results and Business Update on August 15, 2022

Content of the article

The company will host a conference call and webcast at 5:00 p.m. ET

MENLO PARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical-stage biotechnology company leveraging the power of mitochondria and peptides encoded in its genome to develop potential breakthrough therapies targeting chronic and age-related diseases, today announced that the company will release its second quarter 2022 financial results after market close on Monday, August 15, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on company activities.

Advertisement 2

Content of the article

Details for the conference call:

Date: August 15, 2022
Time: 5:00 p.m. ET (2:00 p.m. PT)

Conference audio

  • Call in the United States and Canada: (877) 451-6152
  • International call: (201) 389-0879
  • Conference ID: 13730421

Webcast

  • A simultaneous webcast of the call will be accessible via the Investors section of CohBar’s website at www.cohbar.com.

For those participating in the call for investors or the webcast, please call or tune into the audio of the call approximately 10 minutes before it begins.

An audio replay of the call will be available from 8:00 p.m. Eastern Time on August 15, 2022 until 11:59 p.m. Eastern Time on September 5, 2022. To access the to record, please dial (844) 512-2921 within the United States and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13730421. The audio recording will also be available at www.cohbar. com during the same period.

Advertisement 3

Content of the article

About CohBar

CohBar (NASDAQ: CWBR) is a clinical-stage biotechnology company harnessing the power of mitochondria and the peptides encoded in its genome to develop potential breakthrough therapies targeting chronic and age-related diseases with little or no harm. treatment options. CohBar has acquired a leadership position in the exploration of the mitochondrial genome and its utility for the development of new therapies, including world-renowned expertise in mitochondrial biology, an extensive intellectual property estate, key opinion leaders and disciplined drug discovery and development processes. CohBar uses its Mito+ platform to identify and develop modified versions of natural peptides called analogues to treat a variety of serious diseases, with a focus on diseases involving inflammation and fibrosis.

For more information about the company, visit www.cohbar.com and connect with us on LinkedIn.

contacts:

Jordyn Tarazi
Investor Relations Director
CohBar, Inc.
(650) 445-4441
[email protected]

Advertising

comments

Postmedia is committed to maintaining a lively yet civil discussion forum and encourages all readers to share their views on our articles. Comments can take up to an hour to be moderated before appearing on the site. We ask that you keep your comments relevant and respectful. We have enabled email notifications. You will now receive an email if you receive a reply to your comment, if there is an update to a comment thread you follow, or if a user follows you comments. See our Community Guidelines for more information and details on how to adjust your email settings.

Comments are closed.